+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Late radiation toxicity in Hodgkin lymphoma patients: proton therapy's potential



Late radiation toxicity in Hodgkin lymphoma patients: proton therapy's potential



Journal of Applied Clinical Medical Physics 16(5): 167–178



In 2010, all young patients treated for intrathoracic Hodgkin lymphoma (HL) at one of 10 radiotherapy centers in the province of Quebec received 3D conformal photon therapy. These patients may now be at risk for late effects of their treatment, notably secondary malignancies and cardiac toxicity. We hypothesized that more complex radiotherapy, including intensity-modulated proton therapy (IMPT) and possibly IMRT (in the form of helical tomotherapy (HT)), could benefit these patients. With institutional review board approval at 10 institutions, all treatment plans for patients under the age of 30 treated for HL during a six-month consecutive period of 2010 were retrieved. Twenty-six patients were identified, and after excluding patients with extrathoracic radiation or treatment of recurrence, 20 patients were replanned for HT and IMPT. Neutron dose for IMPT plans was estimated from published measurements. The relative seriality model was used to predict excess risk of cardiac mortality. A modified linear quadratic model was used to predict the excess absolute risk for induction of lung cancer and, in female patients, breast cancer. Model parameters were derived from published data. Predicted risk for cardiac mortality was similar among the three treatment techniques (absolute excess risk of cardiac mortality was not reduced for HT or IMPT (p > 0.05, p > 0.05) as compared to 3D CRT). Predicted risks were increased for HT and reduced for IMPT for secondary lung cancer (p < 0.001, p < 0.001) and breast cancers (p< 0.001, p< 0.001) as compared to 3D CRT.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 058201762

Download citation: RISBibTeXText

PMID: 26699298


Related references

Comparison of passive-beam proton therapy, helical tomotherapy and 3D conformal radiation therapy in Hodgkin's lymphoma female patients receiving involved-field or involved site radiation therapy. Cancer Radiotherapie 20(2): 98-103, 2016

Potential to Reduce Toxicity: Clinical and Dosimetric Predictors of Hypothyroidism After Radiation Therapy With IMRT for Hodgkin Lymphoma. International Journal of Radiation Oncology*biology*physics 99(2): S63-S64, 2017

Late Cardiac Toxicity After Mediastinal Radiation Therapy for Hodgkin Lymphoma: Contributions of Coronary Artery and Whole Heart Dose-Volume Variables to Risk Prediction. International Journal of Radiation Oncology, Biology, Physics 98(5): 1116-1123, 2017

SU-E-T-580: Does Arc Therapy Have the Potential to Improve Radiation Treatment of Hodgkin's Lymphoma Patients?. Medical Physics 39(6part19): 3839, 2012

Cardiac injury as late toxicity of mediastinal radiation therapy for Hodgkin's disease patients. Haematologica 81(2): 132-137, 1996

Cardiac sparing with proton therapy in consolidative radiation therapy for Hodgkin lymphoma. Leukemia and Lymphoma 51(8): 1559-1562, 2010

Predictors of radiation pneumonitis in patients receiving intensity modulated radiation therapy for Hodgkin and non-Hodgkin lymphoma. International Journal of Radiation Oncology, Biology, Physics 92(1): 175-182, 2015

Predictors of Radiation Pneumonitis in Patients Receiving Intensity Modulated Radiation Therapy for Hodgkin and Non Hodgkin Lymphoma. International Journal of Radiation Oncology*biology*physics 93(3): S79-S80, 2015

The Role of Radiation Therapy in Patients With Relapsed or Refractory Hodgkin Lymphoma: Guidelines From the International Lymphoma Radiation Oncology Group. International Journal of Radiation Oncology, Biology, Physics 100(5): 1100-1118, 2018

EP-1870: Selection of the field size for radiation therapy 3D planning in patients with Hodgkin and non-Hodgkin's lymphoma. RadioTherapy and Oncology 111: S312-S313, 2014

Consolidative proton therapy after chemotherapy for patients with Hodgkin lymphoma. Annals of Oncology 28(9): 2179-2184, 2018

Minimizing late effects in children and adults with Hodgkin lymphoma - the beginning of the end for radiation therapy. Leukemia and Lymphoma 49(5): 839-840, 2008

Late cardiac effect of radiation therapy on a young woman with mediastinal Hodgkin's lymphoma. General Thoracic and Cardiovascular Surgery 64(1): 51-54, 2016

Late onset of dropped head syndrome following mantle radiation therapy for Hodgkin lymphoma. Bmj Case Reports 11(1), 2018

Severe valvular toxicity and pericarditis early after radiation therapy in a patient treated for Hodgkin's lymphoma. Turkish Journal of Pediatrics 52(4): 423-425, 2010